Russell Investments Group Ltd. Acquires 125,697 Shares of Humana Inc. (NYSE:HUM)

Russell Investments Group Ltd. increased its position in Humana Inc. (NYSE:HUM) by 59.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 338,801 shares of the insurance provider’s stock after buying an additional 125,697 shares during the period. Russell Investments Group Ltd. owned about 0.28% of Humana worth $154,948,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in HUM. Exchange Traded Concepts LLC grew its stake in shares of Humana by 103.0% in the 3rd quarter. Exchange Traded Concepts LLC now owns 2,883 shares of the insurance provider’s stock worth $1,403,000 after buying an additional 1,463 shares in the last quarter. UMB Bank n.a. lifted its position in Humana by 2.8% in the third quarter. UMB Bank n.a. now owns 805 shares of the insurance provider’s stock worth $392,000 after buying an additional 22 shares during the last quarter. Aaron Wealth Advisors LLC bought a new stake in shares of Humana during the third quarter valued at approximately $213,000. Handelsbanken Fonder AB grew its stake in Humana by 1.3% in the third quarter. Handelsbanken Fonder AB now owns 42,188 shares of the insurance provider’s stock worth $20,525,000 after purchasing an additional 541 shares in the last quarter. Finally, MCF Advisors LLC increased its holdings in Humana by 22.8% during the 3rd quarter. MCF Advisors LLC now owns 3,869 shares of the insurance provider’s stock worth $1,884,000 after purchasing an additional 718 shares during the period. Institutional investors own 92.38% of the company’s stock.

Humana Stock Down 1.8 %

Shares of HUM traded down $5.51 on Friday, reaching $305.90. The company’s stock had a trading volume of 1,213,131 shares, compared to its average volume of 1,914,716. The firm has a fifty day moving average of $327.77 and a 200-day moving average of $394.49. The stock has a market capitalization of $36.86 billion, a PE ratio of 19.05, a PEG ratio of 1.82 and a beta of 0.45. The company has a current ratio of 1.67, a quick ratio of 1.59 and a debt-to-equity ratio of 0.77. Humana Inc. has a twelve month low of $299.23 and a twelve month high of $541.21.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.12 by $1.11. The firm had revenue of $29.61 billion during the quarter, compared to analyst estimates of $28.52 billion. Humana had a return on equity of 17.76% and a net margin of 1.82%. The business’s revenue was up 10.7% compared to the same quarter last year. During the same period last year, the firm posted $9.38 EPS. Equities analysts predict that Humana Inc. will post 16.07 EPS for the current year.

Humana Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.16%. The ex-dividend date of this dividend is Friday, June 28th. Humana’s payout ratio is 22.04%.

Insider Activity

In related news, Director Jorge S. Mesquita bought 545 shares of the company’s stock in a transaction on Tuesday, February 20th. The shares were acquired at an average cost of $367.09 per share, with a total value of $200,064.05. Following the completion of the acquisition, the director now owns 2,578 shares of the company’s stock, valued at approximately $946,358.02. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.32% of the company’s stock.

Analyst Ratings Changes

HUM has been the topic of several analyst reports. The Goldman Sachs Group cut their target price on Humana from $450.00 to $385.00 and set a “buy” rating on the stock in a research note on Wednesday, April 3rd. Truist Financial reiterated a “hold” rating and issued a $550.00 price objective on shares of Humana in a report on Friday, January 19th. Barclays decreased their price target on shares of Humana from $356.00 to $310.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 2nd. Wells Fargo & Company decreased their target price on Humana from $413.00 to $350.00 and set an “overweight” rating for the company in a research note on Monday, April 8th. Finally, TheStreet downgraded Humana from a “b” rating to a “c+” rating in a research note on Monday, January 8th. Eleven equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $433.74.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.